ABY-71A1

N/A

Report date: 2025/01/26 18:30:20

Base Information

Drug NameABY-71A1
Drug Alias Namebeta amyloid antagonist (Abyssinia Biologics)ABY-71A1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsNerve DegenerationAmyloidosisAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAbyssinia Biologics LLC
China Registration ClassN/A

Develop Information

Active CompaniesAbyssinia Biologics LLC
Inactive CompaniesN/A
Active IndicationsNerve DegenerationAmyloidosisAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A